A Phase 3 interventional study of HSK39004 Inhalation Suspension and Placebo control in COPD (Chronic Obstructive Pulmonary Disease), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-22.
Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Pulmonary Disease, Chronic Obstructive by Haisco Pharmaceutical Group Co., Ltd. — 6 open to participants now, 8 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Haisco Pharmaceutical Group Co., Ltd..
Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Haisco Pharmaceutical Group Co., Ltd., this one is the 2nd largest by planned enrollment, is one of 4 that started in 2026, is one of 4 in phase 3, and was the 9th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →6 of the 10 studies in Pulmonary Disease, Chronic Obstructive by Haisco Pharmaceutical Group Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 40–80
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 40–80
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 40–80
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 40–80
By country, each count listing its studies:
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 387 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 300 across the 10 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.
3 of the studies in Pulmonary Disease, Chronic Obstructive by Haisco Pharmaceutical Group Co., Ltd. that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07658339Phase 3Haisco Pharmaceutical Group Co., Ltd.A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD | 2027-06-11 |
| NCT07583849Phase 3Haisco Pharmaceutical Group Co., Ltd.A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD | 2027-09-30 |
| NCT07425210Haisco Pharmaceutical Group Co., Ltd.Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Haisco Pharmaceutical Group Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of HSK39004 Inhalation Suspension in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
Key Inclusion Criteria:
At screening visit (Visit 1):
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 mg BID
Drug: HSK39004 Inhalation Suspension
BID
Drug: Placebo control
Dosage Formulation: HSK39004 Inhalation suspension Dosage 3mg,Twice Daily for 24 weeks
Dosage Formulation: Placebo Inhalation suspension Dosage 0mg,Twice Daily for 24 weeks
Change from Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Week 12
Average FEV1 AUC0-12h was defined as AUC over 12 hours of the FEV1, divided by 12 hours. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing.
Time frame: Baseline (pre-dose on Day 1) and Week 12
Change from Baseline in peak FEV1 within 4 hours after administration at week 4, 8, 12, 18, 24
Peak FEV1 is the maximum value in the 4 hours after dosing. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing.
Time frame: Baseline (pre-dose on Day 1) and Week 4, 8, 12, 18, 24
Change from Baseline in Morning trough FEV1 after administration at week 4, 8, 12, 18, 24
Morning trough FEV1 was the last value collected prior to the morning dose. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing.
Time frame: Baseline (pre-dose on Day 1) and week 4, 8, 12, 18, 24
Change from Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-4h) at Week 4, 8, 12, 18, 24
Average FEV1 AUC0-4h was defined as AUC over 4 hours of the FEV1, divided by 4 hours. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing.
Time frame: Baseline (pre-dose on Day 1) and Week 4, 8, 12, 18, 24
Change From Baseline in the St. George's Respiratory Questionnaire (SGRQ) Total Score at Weeks 12 and 24
The SGRQ questionnaire consists of 17 questions, split into 2 parts. Part 1 consisted of the first 8 questions and was related to the symptoms subdomain. The remaining 9 questions were in Part 2, which were related to the activity and impacts subdomains. The total score was calculated by dividing the summed weights by the maximum possible weight for all items in the questionnaire and expressing the result as a percentage. Score ranging from 0 to 100 and higher scores indicated a worse outcome. Baseline is the score calculated on Day 1.
Time frame: Day1, Weeks 12 and 24
Treatment-emergent adverse event (TEAE) incidence
The incidence of treatment-emergent adverse events (TEAEs), assessed through vital signs, physical examinations, laboratory tests, 12-lead ECG parameters, and detailed adverse event monitoring.
Time frame: From week 1 to week 25
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Jun 2027, 11 months later.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's planned 11 months is below that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HSK39004
Pulmonary Disease, Chronic Obstructive →
Haisco Pharmaceutical Group Co., Ltd. →